These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 26544135)
1. Drug pipeline: 3Q15. DeFrancesco L Nat Biotechnol; 2015 Nov; 33(11):1126. PubMed ID: 26544135 [No Abstract] [Full Text] [Related]
2. Drugs with breakthrough status charm investors. Senior M Nat Biotechnol; 2013 Nov; 31(11):945-7. PubMed ID: 24213748 [No Abstract] [Full Text] [Related]
3. Balancing US patent and FDA approval processes: strategically optimizing market exclusivity. Fernandez DS; Huie JT Drug Discov Today; 2004 Jun; 9(12):509-12. PubMed ID: 15183155 [No Abstract] [Full Text] [Related]
4. Potential pathways for abbreviated approval of generic biologics under existing law and proposed reforms to the law. Dinh TQ Food Drug Law J; 2007; 62(1):77-137. PubMed ID: 17444027 [No Abstract] [Full Text] [Related]
5. Market watch: Upcoming market catalysts in Q3 2016. Ranj T Nat Rev Drug Discov; 2016 Jul; 15(7):449. PubMed ID: 27282354 [No Abstract] [Full Text] [Related]
6. A critical tipping point. Zuckerman MB US News World Rep; 2002 Apr; 132(13):72. PubMed ID: 11993366 [No Abstract] [Full Text] [Related]
7. Obstacles and opportunities in new drug development. Kaitin KI Clin Pharmacol Ther; 2008 Feb; 83(2):210-2. PubMed ID: 18202685 [No Abstract] [Full Text] [Related]
8. New estimates of drug development costs. Frank RG J Health Econ; 2003 Mar; 22(2):325-30. PubMed ID: 12606149 [No Abstract] [Full Text] [Related]
9. [Development of new drugs is too expensive]. Andreasen J Ugeskr Laeger; 2003 May; 165(19):1959-60. PubMed ID: 12795066 [No Abstract] [Full Text] [Related]
10. Costing drug development. Nat Rev Drug Discov; 2003 Apr; 2(4):247. PubMed ID: 12680358 [No Abstract] [Full Text] [Related]
11. Prospects for productivity. Booth B; Zemmel R Nat Rev Drug Discov; 2004 May; 3(5):451-6. PubMed ID: 15136792 [No Abstract] [Full Text] [Related]
12. Balancing government regulation against access to drugs: address to Seton Hall University School of Law, February 16, 2007. Meron D Seton Hall Law Rev; 2007; 37(4):929-39. PubMed ID: 18363219 [No Abstract] [Full Text] [Related]
13. Market watch: Upcoming market catalysts in Q3 2015. Tan C Nat Rev Drug Discov; 2015 Jul; 14(7):451. PubMed ID: 26092947 [No Abstract] [Full Text] [Related]
14. 2013 FDA drug approvals. Mullard A Nat Rev Drug Discov; 2014 Feb; 13(2):85-9. PubMed ID: 24481294 [No Abstract] [Full Text] [Related]
15. Research and development costs for drugs. Riggs TL Lancet; 2004 Jan; 363(9404):184. PubMed ID: 14738789 [No Abstract] [Full Text] [Related]
16. Food and Drug Administration Drug Approval Process: A History and Overview. Williams CT Nurs Clin North Am; 2016 Mar; 51(1):1-11. PubMed ID: 26897420 [TBL] [Abstract][Full Text] [Related]
17. Ethical and financial considerations in third-party support of investigational cancer therapies. Young FE Cancer; 1993 Nov; 72(9 Suppl):2854-8. PubMed ID: 8402519 [TBL] [Abstract][Full Text] [Related]
18. The FDA's drug review process: ensuring drugs are safe and effective. Meadows M FDA Consum; 2002; 36(4):19-24. PubMed ID: 12184298 [No Abstract] [Full Text] [Related]
20. Support for trials of promising medications through the Pharmaceutical Benefits Scheme. Bell KD Med J Aust; 1995 Apr; 162(8):447; author reply 447-8. PubMed ID: 7746194 [No Abstract] [Full Text] [Related] [Next] [New Search]